Yes. As of September 2026, ResMed Inc. (RMD) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.22% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.02% / 30% · Interest income / Revenue 1.50% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.22% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.02% / 33% · Receivables / Mkt Cap (36m) 2.90% / 49% · Interest income / Revenue 1.50% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.22% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.02% / 33.33% · Receivables / Mkt Cap (24m) 2.90% / 33.33% · Interest income / Revenue 1.50% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 7.49% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 16.2% / 33.33% · Receivables / Avg Assets (4Q) 11.9% / 33.33% · Interest income / Revenue 1.50% / 5% | Pass |
| FTSE | Debt / Total Assets 4.99% / 33.33% · (Cash+ST Inv) / Total Assets 12.3% / 33.33% · (Cash+Recv) / Total Assets 24.2% / 33.33% · Interest income / Revenue 1.50% / 5% | Pass |
Yes. As of September 2026, ResMed Inc. (RMD) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. ResMed Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.50% of each dividend: ResMed Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
ResMed Inc. (NYSE: RMD) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $33.6B. The Maz Rating grades it against the other companies in its sector.
ResMed Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $238.75, ResMed Inc. trades at 21.6x trailing earnings, 5.8x sales and 5.7x book value, with an EV/EBITDA of 14.8. Over the last twelve months it generated about $5.7B of revenue and $1.6B of net income. It runs a gross margin of 61.2%, an operating margin of 33.0% and a net margin of 27.8%. It shows return on equity of 25.1%, return on invested capital of 21.2% and a free cash flow yield of 4.8%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 2.65. Over the past 52 weeks the share price ranged from $180.27 to $277.67, with a beta of 0.76.
ResMed Inc. pays a dividend yielding 1.06%, with 22% of earnings paid out. Its Maz Dividend Score is 4.43 out of 5, ranked against the other dividend payers in its sector (Safety 3.90, Growth 3.83, Yield 2.97, Consistency 3.07).
36 Wall Street analyst ratings cover the stock: 14 Buy, 17 Hold and 5 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.